Beam Therapeutics Quarterly Income Statement
NASDAQ: BEAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Beam Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Beam Therapeutics generated $490,000 in revenue, down 94.2% from the same quarter a year earlier. Beam Therapeutics reported a net loss of $122.7 million, compared with a loss of $102.1 million a year earlier. Operating margin was -25827.1%.
Diluted earnings per share came in at -$1.18.
Summary generated from market data by MetaCap's automated system. Methodology
Beam Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 490.00K | 31.74M | 114.11M | 9.70M | 8.47M | 7.47M | 30.07M | 14.27M | 11.77M | 7.41M | 316.19M | 17.19M |
| Revenue growth (YoY) | -94.21% | +324.87% | +279.52% | -32.03% | -28.08% | +0.81% | -90.49% | -17.01% | -41.48% | -69.39% | +1478.04% | +8.82% |
| Operating Expenses | 127.04M | 138.95M | 131.55M | 136.51M | 128.62M | 126.76M | 130.10M | 120.77M | 116.67M | 111.54M | 183.33M | 125.46M |
| Research & Development | 95.10M | 104.52M | 99.28M | 109.77M | 101.76M | 98.82M | 101.44M | 94.26M | 87.04M | 84.82M | 140.08M | 100.05M |
| Operating Income | -126.55M | -107.22M | -17.45M | -126.81M | -120.15M | -119.29M | -100.04M | -106.50M | -104.89M | -104.13M | 132.86M | -108.27M |
| Other Income (Expense) | 3.88M | 12.90M | 261.74M | 14.08M | 18.01M | 10.96M | 9.68M | 9.84M | 13.88M | 5.46M | 11.30M | 12.18M |
| Pretax Income | — | — | 244.30M | -112.73M | -102.29M | — | -90.35M | -96.67M | -91.01M | — | 144.16M | -96.09M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39.00K | 0 | 1.37M | 0 |
| Net Income | -122.68M | -94.32M | 244.30M | -112.73M | -102.14M | -108.33M | -90.35M | -96.67M | -91.05M | -98.67M | 142.80M | -96.09M |
| Net Income growth (YoY) | — | — | — | — | — | — | -163.27% | — | — | — | — | — |
| EPS (Basic) | -1.18 | -0.91 | 2.52 | -1.10 | -1.00 | -1.23 | -1.09 | -1.17 | -1.11 | -1.21 | 1.91 | -1.22 |
| EPS (Diluted) | -1.18 | -0.91 | 2.52 | -1.10 | -1.00 | -1.23 | -1.09 | -1.17 | -1.11 | -1.21 | 1.91 | -1.22 |
| Shares Outstanding (Basic) | 104.33M | 103.26M | — | 102.57M | 102.00M | 87.98M | — | 82.41M | 82.31M | 81.70M | — | 79.02M |
| Shares Outstanding (Diluted) | 104.33M | 103.26M | — | 102.57M | 102.00M | 87.98M | — | 82.41M | 82.31M | 81.70M | — | 79.02M |
| EBITDA | -121.14M | -101.61M | -11.78M | -121.25M | -114.61M | -113.76M | -94.59M | -101.03M | -99.32M | -98.70M | 138.22M | -103.08M |
| Operating Margin | -25827.14% | -337.81% | -15.29% | -1307.60% | -1419.22% | -1596.87% | -332.71% | -746.40% | -891.06% | -1405.29% | 42.02% | -629.72% |
| Net Margin | -25036.33% | -297.18% | 214.09% | -1162.38% | -1206.45% | -1450.20% | -300.51% | -677.47% | -773.45% | -1331.57% | 45.16% | -558.88% |
This table shows 12 quarterly periods of Beam Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow BEAM's reporting calendar. What is a income statement?